Dedicated to identifying the root causes of multiple sclerosis (MS), Genesis Biotech was formally launched in 2009. It grew out of one research center based in Pune, dedicated to finding the link between vascular abnormalities and neuronal degeneration in MS. Today, Somata Genesis, Inc. is paired with clinical affiliations in the USA, Trinidad, W.I. and India. Through these research subsidiaries, thousands of MS patients now receive cutting-edge, comprehensive MS care. In breaking news released May, 2016, Genesis announced that it will be pursuing a simultaneous Phase I clinical trial exploring the use of allogeneic stem cells in the treatment of MS at its American centers.

The announcement followed positive results from a IRB-approved Phase I autologous stem cell trial. In this Phase I trial, MS patients received multiple IV and spinal injections of mononuclear cells derived from their bone marrow (called BM-MNCs). In addition to demonstrating positive safety and tolerability data with autologous stem cells, this Phase I trial was the first time in history that a treatment showed reversal of established disability in MS patients. Phase I patients with MS were observed to have clinical improvements in ambulatory function, limb strength, and bladder control, among other improvements. Click here to view data.